Home > Insider Trading > Filing (0000899243-21-035844)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1098972	Agenus Inc	AGEN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
935679	H Garo Armen	C/O Agenus Inc. 3 Forbes Road Lexington MA 02421	Chairman And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-09-13	119,178	$3.36	852,880	No	4	M	Direct
Common Stock	Disposition	2021-09-13	82,107	$6.50	770,773	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option, right to buy	Disposition	2021-09-13	119,178	$0.00	119,178	$3.36

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2011-12-14	2021-09-14	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	125,969	Indirect	See Footnote
Common Stock	579,000	Indirect	See Footnote

Footnotes

The options subject to the transaction reported on this Form 4 would have expired on September 14, 2021.
Shares are held in Dr. Armen's IRA accounts.
Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 479,000 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 100,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
Represents sales of shares, as a consequence of the exercise of options, to cover Federal, state and local tax withholding requirements and the exercise price payment related to the option exercise. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.55. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.